The Department of Health and Social Care has tied together research, screening and plan delivery in its latest breast cancer announcement. The immediate development is that more than 1,000 people have now joined the FAST-Forward Boost trial, which is testing whether some patients can receive radiotherapy in five days instead of the current three-week course. For patients, the policy case is clear. A successful shortened regimen could remove around 10 hospital visits from treatment, reducing travel, time away from work and family disruption while easing pressure on radiotherapy services.
According to the department, the FAST-Forward Boost trial is running at 39 hospitals across the UK. It is led by The Institute of Cancer Research, London, funded through the National Institute for Health and Care Research, and examines whether a shorter schedule can be combined with an additional targeted boost dose intended to reduce the risk of the cancer returning. That design matters because the study is not simply testing faster treatment for convenience. It is testing whether NHS services can safely shorten a pathway without weakening local cancer control for patients who need an additional dose after standard radiotherapy.
The research timetable remains long. The trial is aiming to recruit 4,830 participants by 2028, follow them for five years and report results in 2033. On that timetable, the 1,000-participant mark is a recruitment milestone rather than a service change. For providers and commissioners, the signal is therefore about direction rather than immediate rollout. If the evidence is positive, shorter radiotherapy could widen capacity, cut patient transport demand and reduce repeated attendances in already busy cancer centres.
The announcement also gives breast cancer policy a named accountability route inside government. Ashley Dalton MP has been appointed as an adviser on delivery of the National Cancer Plan after stepping down as Parliamentary Under-Secretary of State for Public Health and Prevention on 2 March 2026 to manage her health and treatment side effects. The Department says Dalton, who is living with metastatic breast cancer, will advise on where cancer care delivery is off track, whether further intervention is needed and whether the plan is improving quality of life and patient experience. The plan's stated long-term aim is that by 2035, three in four people diagnosed with cancer will be cancer free or living well five years after diagnosis.
On early diagnosis, the department has highlighted stronger uptake of first breast screening invitations. The figure cited is 63.6 per cent, the highest level for a first invitation in the past decade, but the same release notes that around four in 10 women invited for the first time still do not attend. That gap matters because screening remains one of the main routes to earlier diagnosis. Breast Cancer Now says around 30 per cent of female breast cancers in England are diagnosed through screening, usually at an early stage, and that five-year survival is close to 100 per cent when the disease is found at stage 1, compared with 32 per cent at stage 4.
The government has also linked the announcement to two wider programmes already in train. Ministers, the National Institute for Health and Care Research and NHS England are supporting trials that use AI to assist the reading of mammograms, while a three-year partnership with Breast Cancer Now is intended to help women recognise symptoms, access trusted information and obtain support after treatment. That partnership sits within the Renewed Women's Health Strategy. Read together, the measures suggest a pathway approach in which screening, diagnostic support, treatment intensity and post-treatment information are being treated as connected parts of the same policy problem.
For patients in current care pathways, the immediate position is unchanged: the shorter radiotherapy schedule is still under evaluation, and standard clinical decisions remain with treating teams. For the NHS, however, the announcement sets out the areas ministers expect to show progress on under the National Cancer Plan: earlier diagnosis, less burdensome treatment where evidence supports it, and stronger support for people living with and beyond cancer. In policy terms, the significance of the announcement is not only the research milestone. It is the attempt to turn separate commitments on trials, screening uptake, digital tools and patient voice into a delivery agenda that can be measured over time.